Head and neck squamous cell carcinoma (HNSCC), the sixth most common cancer worldwide, has an overall 5-year survival of 50%, which is reduced to 16% where disseminated disease is present at diagnosis. Globally, more than 500,000 new cases are diagnosed per annum. A promising approach to treating HNSCC is gene therapy. Successful gene therapy relies on development of an efficient nonviral vector meeting both safety and clinical acceptable transfection efficiency. We recently developed a tumor-targeted vector for gene delivery on the basis of highly branched nanoscale polyamidoamine (PAMAM) dendrimer. Upregulation of specific signaling molecules such as EPS8 leads to tumor progression. Knockdown of EPS8 in HNSCC resulted in effective inhibition of cancer cell growth, proliferation, and metastasis. In this work, we explored RNA interference technology as a therapeutic tool for treatment of HNSCC with tumor-targeted dendrimer vector as theunderlying carrier.

Dendrimer-EGF-mediated delivery of EPS8 siRNA inhibits tumor cell proliferation and migration

243rd National Meeting (2012)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.